Long COVID might be a bigger problem than researchers thought

Long COVID may be affecting people who were asymptomatic during their infections at a higher rate than researchers expected, a new study conducted by the nonprofit FAIR Health suggests, The New York Times reports.
The study analyzed the health insurance records of 2 million people diagnosed with COVID-19 and found that 23 percent of them later sought medical treatment for new conditions. Among the overall group, rates were highest for people who had dealt with serious bouts of the disease, but even 19 percent of the people who were asymptomatic experienced subsequent medical issues, a figure that surprised FAIR Health's research team, the organization's president Robin Gelburd told the Times.
The study deserves praise for its size and "ability to look across the range of disease severity in a diversity of age groups," said Dr. Helen Chu, a professor of medicine and infectious disease at the University of Washington School of Medicine. At the same time, like most studies, it doesn't paint a complete a picture. Per the Times, it's possible that some of the asymptomatic patients later developed symptoms after their diagnosis, and the study also doesn't compare people who had COVID-19 with those who didn't, so it's not clear whether the medical treatment rates are similar. On the latter point, though, smaller studies have suggested that previously infected patients do, in fact, require treatment more often. Read more at The New York Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Road trip: New England’s maple syrup season
Feature New England is serving up maple syrup in delicious and unexpected ways
By The Week US Published
-
Music Reviews: Mdou Moctar, Panda Bear, and Tate McRae
Feature “Tears of Injustice,” “Sinister Grift,” and “So Close to What”
By The Week US Published
-
What's at stake in the Mahmoud Khalil deportation fight?
Talking Points Vague accusations and First Amendment concerns
By Joel Mathis, The Week US Published
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published